Active Biotech AB (publ) (ACTI.ST)
SEK 0.11
(-7.32%)
SEK 0.11
(-7.32%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -1.67 Million SEK | -12.12% |
| 2022 | -1.49 Million SEK | -16.72% |
| 2021 | -1.28 Million SEK | -119.03% |
| 2020 | 6.72 Million SEK | -20.18% |
| 2019 | 8.42 Million SEK | -57.98% |
| 2018 | 20.05 Million SEK | 42.08% |
| 2017 | 14.11 Million SEK | 39.28% |
| 2016 | 10.13 Million SEK | 42.97% |
| 2015 | 7.08 Million SEK | 212.89% |
| 2014 | 2.26 Million SEK | -97.91% |
| 2013 | 108.14 Million SEK | -50.64% |
| 2012 | 219.09 Million SEK | -6.61% |
| 2011 | 234.59 Million SEK | 1965.81% |
| 2010 | 11.35 Million SEK | 5.42% |
| 2009 | 10.77 Million SEK | -79.85% |
| 2008 | 53.45 Million SEK | 342.63% |
| 2007 | 12.07 Million SEK | -81.8% |
| 2006 | 66.35 Million SEK | 625.08% |
| 2005 | 9.15 Million SEK | -86.87% |
| 2004 | 69.72 Million SEK | 20713.13% |
| 2003 | 335 Thousand SEK | 108.28% |
| 2002 | -4.04 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -400 Thousand SEK | 0.0% |
| 2024 Q3 | -400 Thousand SEK | 0.0% |
| 2024 Q2 | -400 Thousand SEK | 0.0% |
| 2023 FY | -1.67 Million SEK | -12.12% |
| 2023 Q2 | -400 Thousand SEK | 0.0% |
| 2023 Q3 | -400 Thousand SEK | 0.0% |
| 2023 Q1 | -400 Thousand SEK | -100.0% |
| 2023 Q4 | -400 Thousand SEK | 0.0% |
| 2022 Q3 | -400 Thousand SEK | 33.33% |
| 2022 Q1 | -300 Thousand SEK | 0.0% |
| 2022 Q4 | -200 Thousand SEK | 50.0% |
| 2022 Q2 | -600 Thousand SEK | -100.0% |
| 2022 FY | -1.49 Million SEK | -16.72% |
| 2021 Q2 | -300 Thousand SEK | 0.0% |
| 2021 Q3 | -300 Thousand SEK | 0.0% |
| 2021 FY | -1.28 Million SEK | -119.03% |
| 2021 Q4 | -300 Thousand SEK | 0.0% |
| 2021 Q1 | -300 Thousand SEK | -104.82% |
| 2020 Q1 | 500 Thousand SEK | -45.95% |
| 2020 Q2 | - SEK | -100.0% |
| 2020 Q4 | 6.22 Million SEK | 0.0% |
| 2020 FY | 6.72 Million SEK | -20.18% |
| 2020 Q3 | - SEK | 0.0% |
| 2019 FY | 8.42 Million SEK | -57.98% |
| 2019 Q4 | 925 Thousand SEK | 2.78% |
| 2019 Q2 | 900 Thousand SEK | 12.5% |
| 2019 Q1 | 800 Thousand SEK | -83.51% |
| 2019 Q3 | 900 Thousand SEK | 0.0% |
| 2018 FY | 20.05 Million SEK | 42.08% |
| 2018 Q4 | 4.85 Million SEK | 3.21% |
| 2018 Q1 | 4.8 Million SEK | -11.86% |
| 2018 Q3 | 4.7 Million SEK | -17.54% |
| 2018 Q2 | 5.7 Million SEK | 18.75% |
| 2017 Q3 | 5.1 Million SEK | 0.0% |
| 2017 Q1 | 4.7 Million SEK | -33.26% |
| 2017 Q4 | 5.44 Million SEK | 6.78% |
| 2017 Q2 | 5.1 Million SEK | 8.51% |
| 2017 FY | 14.11 Million SEK | 39.28% |
| 2016 Q1 | 3.9 Million SEK | -21.61% |
| 2016 Q4 | 7.04 Million SEK | 71.76% |
| 2016 Q3 | 4.1 Million SEK | 5.13% |
| 2016 Q2 | 3.9 Million SEK | 0.0% |
| 2016 FY | 10.13 Million SEK | 42.97% |
| 2015 Q1 | 2.9 Million SEK | 155.4% |
| 2015 FY | 7.08 Million SEK | 212.89% |
| 2015 Q4 | 4.97 Million SEK | -4.33% |
| 2015 Q3 | 5.2 Million SEK | 62.5% |
| 2015 Q2 | 3.2 Million SEK | 10.34% |
| 2014 Q3 | 2.6 Million SEK | -3.7% |
| 2014 Q4 | -5.23 Million SEK | -301.35% |
| 2014 FY | 2.26 Million SEK | -97.91% |
| 2014 Q1 | 2.1 Million SEK | 155.93% |
| 2014 Q2 | 2.7 Million SEK | 28.57% |
| 2013 Q4 | -3.75 Million SEK | -103.51% |
| 2013 FY | 108.14 Million SEK | -50.64% |
| 2013 Q1 | 2.4 Million SEK | -97.38% |
| 2013 Q3 | 107 Million SEK | 4180.0% |
| 2013 Q2 | 2.5 Million SEK | 4.17% |
| 2012 Q1 | 2.6 Million SEK | -21.21% |
| 2012 Q4 | 91.5 Million SEK | 129.9% |
| 2012 Q3 | 39.8 Million SEK | -57.66% |
| 2012 Q2 | 94 Million SEK | 3515.38% |
| 2012 FY | 219.09 Million SEK | -6.61% |
| 2011 FY | 234.59 Million SEK | 1965.81% |
| 2011 Q1 | 2.7 Million SEK | -5.46% |
| 2011 Q2 | 226.1 Million SEK | 8274.07% |
| 2011 Q3 | 2.6 Million SEK | -98.85% |
| 2011 Q4 | 3.3 Million SEK | 26.92% |
| 2010 Q3 | 2.3 Million SEK | -32.35% |
| 2010 Q2 | 3.4 Million SEK | 21.43% |
| 2010 Q4 | 2.85 Million SEK | 24.17% |
| 2010 Q1 | 2.8 Million SEK | -8.85% |
| 2010 FY | 11.35 Million SEK | 5.42% |
| 2009 Q2 | 3 Million SEK | 36.36% |
| 2009 Q1 | 2.2 Million SEK | 0.0% |
| 2009 Q3 | 2.5 Million SEK | -16.67% |
| 2009 FY | 10.77 Million SEK | -79.85% |
| 2009 Q4 | 3.07 Million SEK | 22.88% |
| 2008 FY | 53.45 Million SEK | 342.63% |
| 2007 FY | 12.07 Million SEK | -81.8% |
| 2006 FY | 66.35 Million SEK | 625.08% |
| 2005 FY | 9.15 Million SEK | -86.87% |
| 2004 FY | 69.72 Million SEK | 20713.13% |
| 2003 FY | 335 Thousand SEK | 108.28% |
| 2002 FY | -4.04 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 98.958% |
| Ziccum AB (publ) | -23.28 Million SEK | 92.807% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 100.484% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 104.008% |
| Mendus AB (publ) | 28.48 Million SEK | 105.88% |
| Genovis AB (publ.) | 54 Million SEK | 103.102% |
| Intervacc AB (publ) | -13.79 Million SEK | 87.857% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 177.153% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 116.812% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 106.245% |
| Aptahem AB (publ) | 2.63 Million SEK | 163.673% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 51.038% |
| Kancera AB (publ) | -1.96 Million SEK | 14.758% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 2275.325% |
| Fluicell AB (publ) | 1.73 Million SEK | 196.375% |
| Saniona AB (publ) | 11.78 Million SEK | 114.218% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 67.266% |
| Biovica International AB (publ) | 6.87 Million SEK | 124.357% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 92.806% |
| AcouSort AB (publ) | 8.38 Million SEK | 119.967% |
| Xintela AB (publ) | 78 Thousand SEK | 2247.436% |
| Abliva AB (publ) | -35.66 Million SEK | 95.303% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 98.86% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 159.672% |
| OncoZenge AB (publ) | 3000.00 SEK | 55933.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 13.212% |
| 2cureX AB (publ) | -37.48 Million SEK | 95.532% |
| CombiGene AB (publ) | -21.29 Million SEK | 92.133% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -295.981% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.148% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.106% |
| Corline Biomedical AB | 28.38 Million SEK | 105.902% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 98.635% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 95.133% |
| I-Tech AB | 27.56 Million SEK | 106.076% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 102.361% |
| Cyxone AB (publ) | 2.61 Million SEK | 164.152% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 149.221% |
| Biosergen AB | -456 Thousand SEK | -267.325% |
| Cantargia AB (publ) | -3.45 Million SEK | 51.463% |
| NextCell Pharma AB | -43.74 Million SEK | 96.171% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 81.782% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 114.931% |
| Nanologica AB (publ) | -76 Thousand SEK | -2103.947% |
| SynAct Pharma AB | -778 Thousand SEK | -115.296% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -767.876% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 87.038% |
| Lipum AB (publ) | 53 Thousand SEK | 3260.377% |
| BioInvent International AB (publ) | 71.46 Million SEK | 102.344% |
| Alzinova AB (publ) | 19.87 Million SEK | 108.428% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 104.614% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 214.489% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -11066.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 201.025% |
| Simris Alg AB (publ) | 2 Million SEK | 183.458% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 53.212% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 104.733% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -59.676% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 153.463% |